Page 2 - Rheumatology Symposium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rheumatology symposium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rheumatology Symposium Today - Breaking & Trending Today

Demographic Factors Influence Medicine Adherence, Satisfaction for RA Treatment

Demographic, psychosocial, and clinical factors along with patient-provider relationships all impact medication adherence and patient satisfaction with RA treatment. ....

College Of Nursing Elizabeth Salt , University Of Kentucky , American College Of Rheumatology Diagnostic Criteria , Elizabeth Salt , Hispanic White , Rheumatology Diagnostic , Medication Adherence Report , Client Satisfaction , Patient Perceived Methotrexate Intolerance Scale , Physician Scale , Patient Health Care Provider Communication , Routine Assessment , Patient Index Data ,

Switching From Adalimumab to a Biosimilar

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar. ....

Jamiet Brogan , Kostas Botsoglou , Sophia Humphreys , Jordan Axelrad , Peter Lio , Switching Therapy , Gastrointestinal Disease ,

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention. ....

Arthritis Care Research , Arthritis Care , Scan Database , Sex Disparities ,

SGLT2 Inhibitors Could Play a Role in Treating Gout

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities. ....

United States , Chio Yokose , Campbellp Dapagliflozin , Merck Ertugliflozin , Campbellp Empagliflozin Jardiance , Mongan Institute , European Congress On Rheumatology , Drug Administration , Rheumatology Allergy Clinical Epidemiology Research Center , Allergy Clinical Epidemiology Research Center , Massachusetts General Hospital , European Congress , Nat Rev Rheumatol , Published December , Reducing Risk , Published October , Published September , Could Lower Gout , Published June ,

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed a dose-response relationship, with higher doses eliciting stronger treatment effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is an immune-mediated inflammatory disease primarily affecting the skin and joints. The immune process is mediated by Interleukin-23, which ....

Minute Medicine Inc , Rating Level , Psoriasis Area , Severity Index , Il 23 , Il 23 Receptor Antagonist , Interleukin 23 Receptor Antagonist , Jnj 77242113 ,